BULLETIN FROM MOBERG’S ANNUAL GENERAL MEETING 2013

Moberg Derma AB’s Annual General Meeting took place on Monday, April 23, 2013 in
the company´s premises in Bromma.
Adoption of the income statements and the balance sheets
The Annual General Meeting (the “Meeting”) approved the income statements and
the balance sheets for the fiscal year 2012.

The Meeting resolved, in accordance with the proposal of the Board of Directors,
that no dividend should be paid for the fiscal year 2012.

The Meeting discharged the Board members and the Chief Executive Officer from
liability for the fiscal year 2012.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Meeting
resolved that the Board of Directors shall consist of eight persons and no
deputies.

The Meeting resolved re-election of all members the Board of Directors; Mats
Pettersson, Wenche Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh, Gustaf
Lindewald, Peter Rothschild, George Aitken-Davies and Peter Wolpert.

Mats Pettersson was re-elected as Chairman of the Board of Directors.

The Meeting resolved, in accordance with the proposal of the Nomination
Committee, that an aggregate fee to Board members of SEK 1,150,000 shall be
paid, of which SEK 300,000 to the Chairman, SEK 250,000 to the Deputy Chairman
and SEK 150,000 per member elected by the Annual General Meeting with the
exception of George Aitken-Davies and Peter Wolpert.

Fees to the Auditors, for a period until the end of the next Annual General
Meeting, are to be paid as per approved invoice.

Nomination Committee
The Meeting resolved, in accordance with the proposal of the Nomination
Committee, that the company shall have a Nomination Committee consisting of four
members. The Nomination Committee shall comprise one representative of each of
the three largest shareholders or owner groups in the company in terms of votes
as per September 30, 2013, besides the Chairman of the Board of Directors.

Principles for remuneration
The Meeting resolved to approve the Board of Director’s proposal for principles
of remuneration to senior executives in Moberg Derma.

Employee Stock Option Plan 2013:1
In accordance with the proposal of the Board of Directors, the Meeting resolved
to adopt an employee stock option plan for employees in the company in the
Company and in the Company’s wholly-owned subsidiary Moberg Pharma North America
LLC. It will be permissible to allot a maximum of 10,000 employee stock options
per plan participant. The Board of Directors and the Chief Executive Officer
shall decide which persons shall be encompassed by the Employee Stock Option
Plan based on position, qualification and individual performance. The maximum
allotment may be adjusted proportionally based on each person's time as an
employee in the Company. The employee stock option plan will not include any
senior executives in the Company, with the exception of Marie Scherlund who is
proposed to be allotted 10,000 employee stock options. In order to secure the
company’s commitments under the employee stock option plan, the Meeting resolved
on a issue of a maximum 77,096 warrants to the company’s wholly-owned subsidiary
Moberg Derma Incentives AB, whereof some of the warrants are intended to hedge
the costs (mainly social security contributions or corresponding taxes) that may
arise from the employee stock option plan. In addition the Meeting resolved to
approve that the subsidiary is entitled to transfer warrants or shares in the
company to the participants in the employee stock option plan, or otherwise
dispose of the warrants, in order to secure Moberg Derma’s commitments and costs
in connection with the employee stock option plan. In the event that all
warrants issued in respect of Employee Stock Option Plan 2013:1 are used to
subscribe for new shares, the company’s share capital will increase by SEK
7,709.60 from SEK 1,081,257.20 to SEK 1,088,966.80. This is equivalent to a
dilution of approximately 0.7 per cent of the shares and votes in the company.

Resolution concerning adoption of new Articles of Association
The Meeting resolved, in accordance with the proposal of the Board of Directors,
to adopt new Articles of Association in which the Company’s registered name is
stated as Moberg Pharma AB (publ). As a result of the acquisition of Alterna LLC
(renamed Moberg Pharma North America LLC), the focus of operations has been
expanded to also include areas other than skin diseases. Skin diseases and
topical technologies for drug delivery will continue to be core areas of the
Company’s operations.

Authorization to issue share
The Meeting resolved, in accordance with the proposal of the Board of Directors,
to authorize the Board of Directors to, within the scope of the articles of
association, with or without deviation from the shareholders’ preferential
right, on one or several occasions during the period until the next Annual
General Meeting, resolve to increase the company’s share capital by issuing new
shares in the company. The total number of shares issued in accordance with this
authorization may be equivalent to a maximum of ten per cent of the shares in
the company at the time of the 2013 Annual General Meeting.

About this information
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 8:00 pm (CET) on April 23rd, 2013.
For further information, please contact:
Peter Wolpert, President and CEO
Telephone: 46 8 522 307 00
Mobile: 46 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: 46 73-355 26 01
E-mail: magnus.persson@mobergderma.se
About Moberg Derma
Moberg Derma AB (publ) is a rapidly growing Swedish pharmaceutical company with
direct sales through its own sales organization in the US and sales through
distributors in more than 35 countries. The company’s product portfolio includes
topical products for the treatment of skin disorders and pain under the brands
Kerasal®, Jointflex®, Emtrix®and Kaprolac®. Emtrix® (Nalox™ in many markets) is
the leading product for the treatment of nail disorders in the Nordic market.
The portfolio is developed further through acquisitions and in-licensing of
products as well as product development with focus on innovative drug delivery
based on proven compounds. Moberg Derma has offices in Stockholm and New Jersey
and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. For further information, please visit:
www.mobergderma.com.